Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice

Behavioural Brain Research

Volumn 225, Issue 1, 2011, Pages 222-229

  Furukawa Hibi, Yoko ^a   Alkam, Tursun ^a   Nitta, Atsumi ^a   Matsuyama, Akihiro ^a   Mizoguchi, Hiroyuki ^b   Suzuki, Kazuhiko ^c   Moussaoui, Saliha ^d   Yu, Qian Sheng ^e   Greig, Nigel H ^e   Nagai, Taku ^a   Yamada, Kiyofumi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c NOVARTIS PHARMA K K   (Japan)

^d NOVARTIS PHARMA AG   (Switzerland)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Acetylcholinesterase; Amyloid ; Butyrylcholinesterase

Indexed keywords

1 PHENETHYLNORCYMSERINE; AMYLOID BETA PROTEIN[1-40]; CHOLINESTERASE INHIBITOR; DONEPEZIL; RIVASTIGMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TARGETING; LOCOMOTION; MALE; MEMORY CONSOLIDATION; MEMORY DISORDER; MOUSE; NITRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECOGNITION; SINGLE DRUG DOSE; TASK PERFORMANCE; TREATMENT DURATION;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INDANS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PEPTIDE FRAGMENTS; PHENYLCARBAMATES; PIPERIDINES; RECOGNITION (PSYCHOLOGY);

EID: 80051518042     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.07.035     Document Type: Article

References (53)

1. Small D.H., McLean C.A. Alzheimer's disease and the amyloid beta protein: what is the role of amyloid?. J Neurochem 1999, 73:443-449.
2. Estus S., Golde T.E., Kunishita T., Blades D., Lowery D., Eisen M., et al. Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. Science 1992, 255:726-728.
3. Golde T.E., Estus S., Younkin L.H., Selkoe D.J., Younkin S.G. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 1992, 255:728-730.
4. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
5. Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989, 245:417-420.
6. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol 1991, 207:367-368.
7. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 1991, 563:311-314.
8. Howlett D.R., Jennings K.H., Lee D.C., Clark M.S., Brown F., Wetzel R., et al. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 1995, 4:23-32.
9. McDonald M.P., Dahl E.E., Overmier J.B., Mantyh P., Cleary J. Effects of an exogenous beta-amyloid peptide on retention for spatial learning. Behav Neural Biol 1994, 62:60-67.
10. Yamada K., Nitta A., Saito T., Hu J., Nabeshima T. Changes in ciliary neurotrophic factor content in the rat brain after continuous intracerebroventricular infusion of beta-amyloid(1-40) protein. Neurosci Lett 1995, 201:155-158.
11. Small D.H., Mok S.S., Bornstein J.C. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2001, 2:595-598.
12. Bullock R., Lane R. Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Curr Alzheimer Res 2007, 4:277-293.
13. Naik R.S., Hartmann J., Kiewert C., Duysen E.G., Lockridge O., Klein J. Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci 2009, 12:79-85.
14. Touchon J., Bergman H., Bullock R., Rapatz G., Nagel J., Lane R. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology. Curr Med Res Opin 2006, 22:49-59.
15. Mesulam M., Guillozet A., Shaw P., Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002, 9:88-93.
16. Darvesh S., Grantham D.L., Hopkins D.A. Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation. J Comp Neurol 1998, 393:374-390.
17. Darvesh S., Hopkins D.A., Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003, 4:131-138.
18. Cerbai F., Giovannini M.G., Melani C., Enz A., Pepeu G. N1phenethyl-norcymserine a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine. Eur J Pharmacol 2007, 572:142-150.
19. Greig N.H., Utsuki T., Ingram D.K., Wang Y., Pepeu G., Scali C., et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005, 102:17213-17218.
20. Butterfield D.A., Drake J., Pocernich C., Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001, 7:548-554.
21. Sultana R., Butterfield D.A. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 2010, 19:341-353.
22. Smith M.A., Richey Harris P.L., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 1997, 17:2653-2657.
23. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21:8370-8377.
24. Perry G., Nunomura A., Hirai K., Zhu X., Perez M., Avila J., et al. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases?. Free Radic Biol Med 2002, 33:1475-1479.
25. Kim H.C., Yamada K., Nitta A., Olariu A., Tran M.H., Mizuno M., et al. Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems in vivo. Neuroscience 2003, 119:399-419.
26. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat Med 2004, 10(Suppl):S18-S25.
27. Walsh D.M., Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004, 44:181-193.
28. Tran M.H., Yamada K., Olariu A., Mizuno M., Ren X.H., Nabeshima T. Amyloid beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J 2001, 15:1407-1409.
29. Alkam T., Nitta A., Mizoguchi H., Itoh A., Nabeshima T. A natural scavenger of peroxynitrites, rosmarinic acid, protects against impairment of memory induced by Abeta(25-35). Behav Brain Res 2007, 180:139-145.
30. Alkam T., Nitta A., Mizoguchi H., Saito K., Seshima M., Itoh A., et al. Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res 2008, 189:100-106.
31. Alkam T., Nitta A., Mizoguchi H., Itoh A., Murai R., Nagai T., et al. The extensive nitration of neurofilament light chain in the hippocampus is associated with the cognitive impairment induced by amyloid beta in mice. J Pharmacol Exp Ther 2008, 327:137-147.
32. Tran M.H., Yamada K., Nakajima A., Mizuno M., He J., Kamei H., et al. Tyrosine nitration of a synaptic protein synaptophysin contributes to amyloid beta-peptide-induced cholinergic dysfunction. Mol Psychiatry 2003, 8:407-412.
33. Maurice T., Lockhart B.P., Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 1996, 706:181-193.
34. Alkam T., Nitta A., Furukawa-Hibi Y., Niwa M., Mizoguchi H., Yamada K., et al. Oral supplementation with Leu-Ile, a hydrophobic dipeptide, prevents the impairment of memory induced by amyloid beta in mice via restraining the hyperphosphorylation of extracellular signal-regulated kinase. Behav Brain Res 2010, 210:184-190.
35. Yu Q., Holloway H.W., Utsuki T., Brossi A., Greig N.H. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J Med Chem 1999, 42:1855-1861.
36. Nakajima A., Yamada K., Nagai T., Uchiyama T., Miyamoto Y., Mamiya T., et al. Role of tumor necrosis factor-alpha in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci 2004, 24:2212-2225.
37. Nagai T., Takuma K., Kamei H., Ito Y., Nakamichi N., Ibi D., et al. Dopamine D1 receptors regulate protein synthesis-dependent long-term recognition memory via extracellular signal-regulated kinase 1/2 in the prefrontal cortex. Learn Mem 2007, 14:117-125.
38. Nitta A., Itoh A., Hasegawa T., Nabeshima T. Beta-Amyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 1994, 170:63-66.
39. Haley G.E., Berteau-Pavy F., Berteau-Pavy D., Raber J. Novel image-novel location object recognition task sensitive to age-related cognitive decline in nondemented elderly. Age (Dordr) 2011.
40. Werheid K., Clare L. Are faces special in Alzheimer's disease? Cognitive conceptualisation, neural correlates, and diagnostic relevance of impaired memory for faces and names. Cortex 2007, 43:898-906.
41. Games D., Khan K.M., Soriano F.G., Keim P.S., Davis D.L., Bryant K., et al. Lack of Alzheimer pathology after beta-amyloid protein injections in rat brain. Neurobiol Aging 1992, 13:569-576.
42. Wise L.E., Iredale P.A., Stokes R.J., Lichtman A.H. Combination of rimonabant and donepezil prolongs spatial memory duration. Neuropsychopharmacology 2007, 32:1805-1812.
43. Luth H.J., Munch G., Arendt T. Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 2002, 953:135-143.
44. Vodovotz Y., Lucia M.S., Flanders K.C., Chesler L., Xie Q.W., Smith T.W., et al. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med 1996, 184:1425-1433.
45. Webster B., Hansen L., Adame A., Crews L., Torrance M., Thal L., et al. Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease. J Neuropathol Exp Neurol 2006, 65:142-151.
46. Giovannini M.G., Scali C., Prosperi C., Bellucci A., Vannucchi M.G., Rosi S., et al. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis 2002, 11:257-274.
47. Boyd-Kimball D., Castegna A., Sultana R., Poon H.F., Petroze R., Lynn B.C., et al. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 2005, 1044:206-215.
48. Nathan C., Calingasan N., Nezezon J., Ding A., Lucia M.S., La Perle K., et al. Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med 2005, 202:1163-1169.
49. Rapoport M., Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J Neurochem 2000, 74:125-133.
50. Diaz A., Mendieta L., Zenteno E., Guevara J., Limon I.D. The role of NOS in the impairment of spatial memory and damaged neurons in rats injected with amyloid beta 25-35 into the temporal cortex. Pharmacol Biochem Behav 2011, 98:67-75.
51. Rao A.A., Sridhar G.R., Das U.N. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 2007, 69:1272-1276.
52. Rosas-Ballina M., Tracey K.J. Cholinergic control of inflammation. J Intern Med 2009, 265:663-679.
53. Hwang J., Hwang H., Lee H.W., Suk K. Microglia signaling as a target of donepezil. Neuropharmacology 2010, 58:1122-1129.